{"organizations": [], "uuid": "86cd2bd1440ef07e1a2045cbf90763ac5e9e70d7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/5", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/26/pr-newswire-boston-scientific-completes-1-point-0-billion-offering-of-senior-notes.html", "country": "US", "domain_rank": 767, "title": "Boston Scientific Completes $1.0 Billion Offering of Senior Notes", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-27T00:05:00.000+02:00", "replies_count": 0, "uuid": "86cd2bd1440ef07e1a2045cbf90763ac5e9e70d7"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/26/pr-newswire-boston-scientific-completes-1-point-0-billion-offering-of-senior-notes.html", "ord_in_thread": 0, "title": "Boston Scientific Completes $1.0 Billion Offering of Senior Notes", "locations": [], "entities": {"persons": [], "locations": [{"name": "mass.", "sentiment": "none"}, {"name": "marlborough", "sentiment": "none"}], "organizations": [{"name": "boston scientific completes", "sentiment": "negative"}, {"name": "boston scientific corporation", "sentiment": "negative"}, {"name": "nyse", "sentiment": "negative"}, {"name": "company", "sentiment": "none"}, {"name": "boston scientific boston scientific", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "MARLBOROUGH, Mass., Feb. 26, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) completed a public offering of $1.0 billion aggregate principal amount of its 4.000% senior notes due March 1, 2028.\nThe Company previously announced that it intends to use the net proceeds from the offering to redeem its 2.650% notes due October 2018, of which $600 million aggregate principal amount was outstanding as of the date hereof, and to repay short term debt and to pay related fees, expenses and premiums. Following the completion of the offering, the Company will provide the trustee with redemption notices to redeem the October 2018 notes.\nAbout Boston Scientific\nBoston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.\nCautionary Statement Regarding Forward-Looking Statements\nThis press release contains within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like \"anticipate,\" \"expect,\" \"project,\" \"believe,\" \"plan,\" \"may,\" \"estimate,\" \"intend\" and similar words. These are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These include, among other things, statements regarding our proposed offering and intended use of proceeds. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our . These ricks and uncertainties, in some cases, have affected and in the future could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our .\nRisks and uncertainties that may cause such differences include, among other things: future economic, competitive, political, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation and governmental investigations; financial market conditions; and future business decisions made by us and our competitors, all of which are difficult or impossible to predict accurately and many of which are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the . This cautionary statement is applicable to all contained in this document.\nCONTACT:\nMedia:\nKate Haranis\nInvestors:\nSusie Lisa, CFA\n508-683-6585 (office)\n508-683-5565 (office)\nMedia Relations\nInvestor Relations\nBoston Scientific Corporation\nBoston Scientific Corporation\nkate.haranis@bsci.com\nBSXInvestorRelations@bsci.com\nView original content with multimedia: http://www.prnewswire.com/news-releases/boston-scientific-completes-10-billion-offering-of-senior-notes-300604348.html\nSOURCE Boston Scientific Corporation", "external_links": ["http://www.prnewswire.com/news-releases/boston-scientific-completes-10-billion-offering-of-senior-notes-300604348.html"], "published": "2018-02-27T00:05:00.000+02:00", "crawled": "2018-02-27T00:56:52.032+02:00", "highlightTitle": ""}